Sun Pharma.Inds.
Sun Pharma.Inds. Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
From Sun Pharma.Inds.'s Q2 FY26 earnings-call transcript · updated 24 Aug 2026.
Revenue & Sales Performance
- Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue.
- U.S. Innovative Medicine sales have surpassed generics for the first time, indicating growth focus.
- India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches.
- Specialty products like ILUMYA expected to continue prescription growth due to expanding markets.
- Targeted treatments like Leqselvi market expected to grow with increasing prescriber confidence and payer coverage.
- GLP-1 market described as very exciting with expected growth; Sun Pharma aims to participate actively.
- New product launches (e.g., Unloxcyt) supported by $100 million incremental spend, with anticipation of increased expenses into H2 FY26.
- Overall, the company anticipates continued growth in innovative medicines and specialty segments, with generics business being stable but lower growth.
Profitability & Margins
See what Sun Pharma.Inds. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17).
- Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12).
- Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6).
- Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6).
- Manufacturing footprint in the U.S. is being constantly assessed with openness to increase U.S.-based manufacturing given policy developments (Page 16, 11).
- No detailed disclosures on capacity plans for GLP-1 drugs or innovative molecules yet (Page 16).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharma.Inds. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Sun Pharma.Inds. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹14.6K Cr, net profit ₹2.7K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharmaceutical Industries Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
- Sudeep Pharma Ltd (Q2 FY26)
NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area. Key concall takeaways…
Frequently Asked Questions
What were Sun Pharma.Inds. Q2 FY26 results?
Global Innovative Medicines sales up 16.4% in Q2 FY26; strong growth expected to continue. Sun Pharma expects normalized tax rate around 25% for the full year, up from prior lower rates due to expiring tax benefits.
What is Sun Pharma.Inds. share price analysis?
Sun Pharma.Inds. currently shows a neutral. The stock trades at a P/E of 36.1 with a market cap of ₹456,449 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma.Inds. planning capital expenditure?
Sun Pharma undertook short-term borrowings linked to the recent acquisition, expected to normalize in coming quarters (Page 17). - Investment in subsidiaries mainly relates to the Checkpoint acquisition (Page 12). - Increase in intangible assets primarily due to Checkpoint acquisition (~$471 million), Leqselvi (~$300 million), and milestone payments like ODOMZO (Page 6). - Specialty launches (Leqselvi and Unloxcyt) are supported by incremental spend of around $100 million in the fiscal year, with expense ramp-up expected in Q3 and Q4 (Page 6). - Manufacturing footprint in the U.S.
Keep Sun Pharma.Inds. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.